Log in

Protagonist Therapeutics Stock Price, News & Analysis (NASDAQ:PTGX)

$11.59
-0.48 (-3.98 %)
(As of 10/21/2019 08:48 AM ET)
Today's Range
$11.32
Now: $11.59
$12.11
50-Day Range
$10.81
MA: $13.25
$16.07
52-Week Range
$5.49
Now: $11.59
$16.67
Volume79,831 shs
Average Volume163,215 shs
Market Capitalization$304.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.92 million
Book Value$4.65 per share

Profitability

Net Income$-38,920,000.00
Net Margins-209.02%

Miscellaneous

Employees64
Market Cap$304.59 million
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.


Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) released its earnings results on Wednesday, August, 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.90. The firm earned ($8.19) million during the quarter, compared to analyst estimates of $10.77 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 62.50%. View Protagonist Therapeutics' Earnings History.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Protagonist Therapeutics.

What price target have analysts set for PTGX?

5 brokers have issued 12 month price objectives for Protagonist Therapeutics' shares. Their predictions range from $17.00 to $29.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $21.50 in the next year. This suggests a possible upside of 85.5% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.

What is the consensus analysts' recommendation for Protagonist Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.

Has Protagonist Therapeutics been receiving favorable news coverage?

Headlines about PTGX stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Protagonist Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Protagonist Therapeutics.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,080,000 shares, an increase of 8.1% from the August 30th total of 998,900 shares. Based on an average trading volume of 207,800 shares, the days-to-cover ratio is currently 5.2 days. Currently, 5.4% of the shares of the stock are sold short. View Protagonist Therapeutics' Current Options Chain.

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)
  • Dr. Richard S. Shames, Chief Medical Officer (Age 59)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
  • Dr. Mark Smythe, VP of Technology (Age 54)
  • Dr. Samuel R. Saks, Chief Devel. Officer (Age 64)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tuttle Tactical Management (0.09%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was purchased by a variety of institutional investors in the last quarter, including Tuttle Tactical Management and Meeder Asset Management Inc.. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $11.59.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $304.59 million and generates $30.92 million in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.View Additional Information About Protagonist Therapeutics.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is http://www.protagonist-inc.com/.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]


MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Back-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel